SPTLC1 and amyotrophic lateral sclerosis: This has therapeutic consequences, as supplementing L-serine in HSAN1 patients should suppress 1-deoxySL formation and slow disease progression, whereas L-serine supplemention in SPTLC1-ALS patients might worsen the phenotype by stimulating the synthesis of canonical SLs.